No quiet surrender: Molecular guardians in multiple sclerosis brain

Journal of Clinical Investigation

Volumn 125, Issue 4, 2015, Pages 1371-1378

  Steinman, Lawrence ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCYSTEINE; ALPHA4 INTEGRIN; AMYLOID PRECURSOR PROTEIN; BETA INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; CYSTAMINE; CYSTATHIONINE; CYSTATHIONINE GAMMA LYASE; CYSTEINE; ENDOTHELIAL PROTEIN C RECEPTOR; GAMMA INTERFERON; GASOTRANSMITTER; GLATIRAMER; GLUTATHIONE; GLUTATHIONE SYNTHASE; GLUTATHIONE TRANSFERASE; HEME OXYGENASE 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 27; KELCH LIKE ECH ASSOCIATED PROTEIN 1; LACTOSYLCERAMIDE; NATALIZUMAB; NERVE GROWTH FACTOR; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLSERINE; PROTEINASE ACTIVATED RECEPTOR 1; SERINE PROTEINASE INHIBITOR; TRANSCRIPTION FACTOR NRF2; ALPHA CRYSTALLIN; AMYLOID; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CELL RECEPTOR; CRYAB PROTEIN, HUMAN; CYTOKINE; LIPID; NERVE PROTEIN; NEUROPROTECTIVE AGENT;

ADAPTIVE IMMUNITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; B LYMPHOCYTE; BLOOD BRAIN BARRIER; BRAIN DAMAGE; CELL MIGRATION; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; FEMALE; GLUTATHIONE METABOLISM; HUMAN; LYMPHOCYTE PROLIFERATION; LYMPHOID CELL; MACROPHAGE; MALE; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVE REGENERATION; NERVOUS SYSTEM INFLAMMATION; NEURAL STEM CELL; NEUROPROTECTION; NONHUMAN; OXIDATION REDUCTION STATE; PELIZAEUS MERZBACHER DISEASE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; T LYMPHOCYTE; BRAIN; CHEMISTRY; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATION; LYMPHOCYTE SUBPOPULATION; METABOLISM; MYELIN SHEATH; OXIDATIVE STRESS; PATHOLOGY; PHYSIOLOGY;

ALPHA-CRYSTALLIN B CHAIN; AMYLOID; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; BRAIN; CYTOKINES; FEMALE; GAMMA-AMINOBUTYRIC ACID; GASOTRANSMITTERS; HUMANS; INFLAMMATION; LIPIDS; LYMPHOCYTE SUBSETS; MALE; MULTIPLE SCLEROSIS; MYELIN SHEATH; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SERPINS;

EID: 84926369953     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI74255     Document Type: Review

References (99)

1. Steinman L. Immunology of relapse and remission in multiple sclerosis. Annu Rev Immunol. 2014;32:257-281.
2. Fitzgerald DC, et al. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat Immunol. 2007; 8(12):1372-1379.
3. Fitzgerald DC, et al. Independent and interdependent immunoregulatory effects of IL-27, IFN-β, and IL-10 in the suppression of human Th17 cells and murine experimental autoimmune encephalomyelitis. J Immunol. 2013;190(7):3225-3234.
4. Murugaiyan G, Mittal A, Weiner HL. Identification of an IL-27/osteopontin axis in dendritic cells and its modulation by IFN-α limits IL-17-mediated autoimmune inflammation. Proc Natl Acad Sci U S A. 2010;107(25):11495-11500.
5. Axtell RC, et al. T helper type 1 and 17 cells determine efficacy of IFN-β in multiple sclerosis and experimental encephalomyelitis. Nature Med. 2010;16(4):406-412.
6. Han MH, et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature. 2008;451(7182):1076-1081.
7. Brinkmann V, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov. 2010;9(11):883-897.
8. Choi JW, et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci U S A. 2011;108(2):751-756.
9. Calabresi PA, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(6):545-556.
10. Khatri B, et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol. 2011;10(6):520-529.
11. Czech B, et al. The immunomodulatory sphingosine 1-phosphate analog FTY720 reduces lesion size and improves neurological outcome in a mouse model of cerebral ischemia. Biochem Biophys Res Commun. 2009;389(2):251-256.
12. Bhat R, et al. Inhibitory role for GABA in autoimmune inflammation. Proc Natl Acad Sci U S A. 2010;107(6):2580-2585.
13. Paul BD, et al. Cystathionine α-lyase deficiency mediates neurodegeneration in Huntington's disease. Nature. 2014;509(7498):96-101.
14. Morikawa T, et al. Hypoxic regulation of the cerebral microcirculation is mediated by a carbon monoxide-sensitive hydrogen sulfide pathway. Proc Natl Acad Sci U S A. 2012;109(4):1293-1298.
15. Ho PP, et al. Identification of naturally occurring fatty acids of the myelin sheath that resolve neuroinflammation. Sci Transl Med. 2012;4(137):137ra73.
16. Linker RA, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain. 2011;134(pt 3):678-692.
17. Ghoreschi K, et al. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med. 2011;208(11):2291-2303.
18. Lehmann D, Karussis D, Misrachi-Koll R, Shezen E, Ovadia H, Abramsky O. Oral administration of the oxidant-scavenger N-acetyl-L-cysteine inhibits acute experimental autoimmune encephalomyelitis. J Neuroimmunol. 1994;50(1):35-42.
19. Oh K, Park HB, Seo MW, Byoun OJ, Lee DS. Transglutaminase 2 exacerbates experimental autoimmune encephalomyelitis through positive regulation of encephalitogenic T cell differentiation and inflammation. Clin Immunol. 2012;145(2):122-132.
20. Stadelmann C, et al. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain. 2002;125(pt 1):75-85.
21. Kerschensteiner M, et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med. 1999;189(5):865-870.
22. Zhang MA, et al. Peroxisome proliferator-activated receptors (PPAR)-a and-α regulate IFN and IL-17A production by human T cells in a sex-specific way. Proc Natl Acad Sci U S A. 2012;109(24):9505-9510.
23. Lovett Racke AE, et al. Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J Immunol. 2004;172(9):5790-5798.
24. Mukundan L, et al. PPAR-γ senses and orchestrates clearance of apoptotic cells to promote tolerance. Nature. 2009;15(11):1266-1272.
25. Walsh LA, Tone M, Thiru S, Waldmann H. The CD59 antigen - a multifunctional molecule. Tissue Antigens. 1992;40(5):213-220.
26. Davoust N, Nataf S, Reiman R, Holers MV, Campbell IL, Barnum SR. Central nervous system-targeted expression of the complement inhibitor sCrry prevents experimental allergic encephalomyelitis. J Immunol. 1999;163(12):6551-6556.
27. Esmon CT. Crosstalk between inflammation and thrombosis. Maturitas. 2004;47(4):305-314.
28. Eddleston M, de la Torre JC, Oldstone MB, Loskutoff DJ, Edgington TS, Mackman N. Astrocytes are the primary source of tissue factor in the murine central nervous system. A role for astrocytes in cerebral hemostasis. J Clin Invest. 1993;92(1):349-358.
29. Gerlitz B, Grinnell BW. Mutation of protease domain residues Lys37-39 in human protein C inhibits activation by the thrombomodulin-thrombin complex without affecting activation by free thrombin. J Biol Chem. 1996;271(37):22285-22288.
30. Grant JL, et al. Reversal of paralysis and reduced inflammation from peripheral administration of β-amyloid in TH1 and TH17 versions of experimental autoimmune encephalomyelitis. Sci Transl Med. 2012;4(145):145ra105.
31. Kurnellas MP, Adams CM, Sobel RA, Steinman L, Rothbard JR. Amyloid fibrils composed of hexameric peptides attenuate neuroinflammation. Sci Transl Med. 2013;5(179):179ra42.
32. Weinger JG, et al. Mice devoid of Tau have increased susceptibility to neuronal damage in myelin oligodendrocyteglycoprotein-induced experimental autoimmune encephalomyelitis. J Neuropathol Exp Neurol. 2012;71(5):422-433.
33. Gourdain P, Ballerini C, Nicot AB, Carnaud C. Exacerbation of experimental autoimmune encephalomyelitis in prion protein (PrPc)-null mice: evidence for a critical role of the central nervous system. J Neuroinflammation. 2012;9:25.
34. Ji Z, Ke ZJ, Geng JG. SAP suppresses the development of experimental autoimmune encephalomyelitis in C57BL/6 mice. Immunol Cell Biol. 2012;90(4):388-395.
35. Ousman SS, et al. Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination. Nature. 2007;448(7152):474-479.
36. Steinman L. The discovery of natalizumab, a potent therapeutic for multiple sclerosis. J Cell Biol. 2012;199(3):413-416.
37. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against a4β1 integrin. Nature. 1992;356(6364):63-66.
38. Polman CH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.
39. Rudick RA, et al. Natalizumab plus interferon β-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911-923.
40. Rudick R, Polman C, Clifford D, Miller D, Steinman L. Natalizumab: bench to bedside and beyond. JAMA Neurol. 2013;70(2):172-182.
41. Lock C, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med. 2002;8(5):500-508.
42. Tzartos JS, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol. 2008;172(1):146-155.
43. Matusevicius D, et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler. 1999;5(2):101-104.
44. Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet. 1987;329(8538):893-895.
45. Panitch HS, Hirsch RL, Schindler J, Johnson KP. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology. 1987;37(7):1097-1102.
46. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med. 2007;13(2):139-145.
47. Sweeney CM, et al. IL-27 mediates the response to IFN-β therapy in multiple sclerosis patients by inhibiting Th17 cells. Brain Behav Immun. 2011;25(6):1170-1181.
48. Norden DM, Fenn AM, Dugan A, Godbout JP. TGFβ produced by IL-10 redirected astrocytes attenuates microglial activation. Glia. 2014;62(6):881-895.
49. Guo B, Chang EY, Cheng G. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J Clin Invest. 2008;118(5):1680-1690.
50. Shinohara M, Kim JH, Garcia VA, Cantor H. Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin. Immunity. 2008;29(1):68-78.
51. Linker RA, et al. CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat Med. 2002;8(6):620-624.
52. Linker RA, et al. Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis. Brain. 2010;133(pt 8):2248-2263.
53. Zivadinov R, et al. Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor. Hum Mol Genet. 2007;16(22):2659-2668.
54. Friese M, Schattling B, Fugger L. Mechanisms of neurodegeneration and axonal dystfunction in multiple sclerosis. Nat Rev Neurol. 2014;10(4):225-238.
55. Valdo P, et al. Enhanced expression of NGF receptors in multiple sclerosis lesions. J Neuropathol Exp Neurol. 2002;61(1):91-98.
56. Villoslada P, et al. Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system. J Exp Med. 2000;191(10):1799-1806.
57. Colombo E, et al. Stimulation of the neurotrophin receptor TrkB on astrocytes drives nitric oxide production and neurodegeneration. J Exp Med. 2012;209(3):521-535.
58. Tian J, Chau C, Hales TG, Kaufman DL. GABA(A) receptors mediate inhibition of T cell responses. J Neuroimmunol. 1999;96(1):21-28.
59. Diop L, Raymond F, Fargeau H, Petoux F. Chovet M, Doherty AM. Pregabalin (CI-1008) inhibits the trintorbenzene sulfonic acid-induced chronic colonic allodynia in the rat. J Pharmacol Exp Ther. 2002;302(3):1013-1022.
60. Tian J, Lu Y, Zhang H, Chau CH, Dang HN, Kaufman DL. Gamma-aminobutyric acid inhibits T cell autoimmunity and the development of inflammatory responses in a mouse type 1 diabetes model. J Immunol. 2004;173(8):5298-5304.
61. Yang G, et al. Hydrogen sulfide protects against cellular senescence via S-sulfhydration of Keap1 and activation of Nrf2. Antioxid Redox Signal. 2013;18(15):1906-1919.
62. Gold R, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098-1107.
63. Fox R, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087-1097.
64. Scannevin RH, et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther. 2012;341(1):274-284.
65. Yang G, et al. H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine γ-lyase. Science. 2008;322(5901):587-590.
66. Karpuj MV, et al. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med. 2002;8(2):143-149.
67. Igarashi S, et al. Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch. Nat Genet. 1998;18(2):111-117.
68. Borrell-Pagès M, et al. Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J Clin Invest. 2006;116(5):1410-1424.
69. Sun L, Xu S, Zhou M, Wang C, Wu Y, Chan P. Effects of cysteamine on MPTP-induced dopaminergic neurodegeneration in mice. Brain Res. 2010;1335:74-82.
70. Raptor Announces Clinical Results With RP103 in Huntington's Disease Phase 2/3 Trial [press release]. Novato, California, USA: Globe Newswire; February 20, 2014.
71. Prundean A, Youssov K, Humbert S, Bonneau D, Verny C. A phase II, open-label evaluation of cysteamine tolerability in patients with Huntington's disease. Mov Disord. 2015;30(2):288-289.
72. Lanning BR, et al. A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors. Nat Chem Biol. 2014;10(9):760-768.
73. Graeber MB. Neuroinflammation: no rose by any other name. Brain Pathol. 2014;24(6):620-622.
74. Steinman L. Why are prions and amyloid structures immune suppressive and other intriguing questions facing neuroimmunologists in the future. Rev Neurol (Paris). 2014;170(10):602-607.
75. Chora AA, et al. Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation. J Clin Invest. 2007;117(2):438-447.
76. Motterlini R, Otterbein LE. The therapeutic potential of carbon monoxide. Nat Rev Drug Discov. 2010;9(9):728-743.
77. Wilson AJ, Kerns JK, Callahan JF, Moody CJ. Keap calm, and carry on covalently. J Med Chem. 2013;56(19):7463-7476.
78. Sun J, et al. Hemoprotein Bach1 regulates enhancer availability of heme oxygenase-1 gene. EMBO J. 2002;21(19):5216-5224.
79. Reichard JF, Motz GT, Puga A. Heme oxygenase-1 induction by NRF2 requires inactivation of the transcriptional repressor BACH1. Nucleic Acids Res. 2007;35(21):7074-7086.
80. Pamplona A, et al. Heme oxygenase-1 and carbon monoxide suppress the pathogenesis of experimental cerebral malaria. Nat Med. 2007;13(6):703-710.
81. Mayo L, et al. Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation. Nat Med. 2014;20(10):1147-1156.
82. Dunn SE, et al. Peroxisome proliferator-activated receptor (PPAR)a expression in T cells mediates gender differences in development of T cell-mediated autoimmunity. J Exp Med. 2007;204(2):321-330.
83. Hucke S, et al. Licensing of myeloid cells promotes central nervous system autoimmunity and is controlled by peroxisome proliferator-activated receptor? Brain. 2012;135(pt 5):1586-1605.
84. Chabas D, et al. The influence of the pro-inflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science. 2001;294(5547):1731-1735.
85. Steinman L, Zamvil S. Transcriptional analysis of targets in multiple sclerosis. Nat Rev Immunol. 2003;3(6):483-492.
86. Zamvil SS, Steinman L. Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis. Neuron. 2003;38(5):685-688.
87. van Noort JM, et al. The small heat-shock protein alpha B-crystallin as candidate autoantigen in multiple sclerosis. Nature. 1995;375(6534):798-801.
88. Laganowsky A, et al. Atomic view of a toxic amyloid small oligomer. Science. 2012;335(6073):1228-1231.
89. Steinman L. Nuanced roles of cytokines in three major human brain disorders. J Clin Invest. 2008;118(11):3557-3563.
90. Karran E, Hardy J. A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann Neurol. 2014;76(2):185-205.
91. Hyman BT, Sorger P. Failure analysis of clinical trials to test the amyloid hypothesis. Ann Neurol. 2014;76(2):159-161.
92. Steinman L, Ousman SS, Robinson WH, inventors; The Board Of Trustees Of The Leland Stanford Junior University, assignee. Alpha B-crystallin as a therapy for rheumatoid arthritis. US patent 7,875,589. December 11, 2007.
93. Steinman L, Ousman SS, Robinson WH, inventors; The Board Of Trustees Of The Leland Stanford Junior University, assignee. Alpha B-crystallin as a therapy for ischemia or inflammation. US patent 8,771,689. June 23, 2011.
94. Pangratz-Fuehrer S, Kaur K, Ousman SS, Steinman L, Liao YJ. Functional rescue of experimental ischemic optic neuropathy with aB-crystallin. Eye (Lond). 2011;25(6):809-817.
95. Velotta JB, et al. aB-crystallin improves murine cardiac function and attenuates apoptosis in human endothelial cells exposed to ischemia-reperfusion. Ann Thorac Surg. 2011;91(6):1907-1913.
96. Arac A, et al. Systemic augmentation of alphaB-crystallin provides therapeutic benefit twelve hours post-stroke onset via immune modulation. Proc Natl Acad Sci U S A. 2011;108(32):13287-13292.
97. Scolding NJ, Morgan BP, Houston WA, Linington C, Campbell AK, Compston DA. Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement. Nature. 1989;339(6226):620-622.
98. Subramanian S, et al. Sustained expression of circulating human alpha-1 antitrypsin reduces inflammation, increases CD4+FoxP3+ Treg cell population and prevents signs of experimental autoimmune encephalomyelitis in mice. Metab Brain Dis. 2011;26(2):107-113.
99. Guo H, et al. An activated protein C analog stimulates neuronal production by human neural progenitor cells via a PAR1-PAR3-S1PR1-Akt pathway. J Neurosci. 2013;33(14):6181-6190.